A Co-localized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence Population
We report the Hepatitis C prevalence and evaluate the impact of the integrated clinic on the Hepatitis C cascade of care.
Conditions: Hepatitis C; Telemedicine Intervention: Other: Telemedicine Sponsor: University of La Laguna Not yet recruiting
Publication date: Available online 1 June 2020Source: Journal of Hospital InfectionAuthor(s): Carlo Balmelli, Giorgio Merlani, Gladys Martinetti, Danuta Reinholz, Stefania Paolucci, Fausto Baldanti, Antonio Piralla, Filippo Del Grande, Enos Bernasconi
In conclusion, the world of psychiatry is a possible hidden reservoir of HCV and, as such, a part of the challenge for eliminating the virus. Patients, families, and caregivers will have to be correctly sensitized and trained to play their role in the process. Specific investigations will be required to better understand why such an increased prevalence of HCV is observed in this population. Specific adaptations of the cascade of care within psychiatric settings, including access to treatment, will need to be designed, implemented, and evaluated for reaching micro-elimination of HCV in psychiatry. PMID: 32473777 [PubMe...
Journal of Interferon&Cytokine Research, Ahead of Print.
Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis worldwide and kills more Americans than 59 other infections, including HIV and tuberculosis, combined. While direct-acting antiviral (DAA) treatments are effective, limited uptake of therapy, particularly in high-risk groups, remains a substantial barrier to eliminating HCV. We developed...
Dalton Trans., 2020, Accepted Manuscript DOI: 10.1039/D0DT01408G, PaperSheta Mohamed Sheta, Said M. El-Sheikh, Diaa I. Osman, Aliaa M.S. Salem, Omnia Ali, Farid A Harraz, Wafaa Gh Shousha, Madiha Shoeib, Sherif Shawky, Dionysios D. Dionysiou Hepatitis-C virus ribonucleic acid (HCV-RNA) recognition and quantification based on real-time polymerase chain reaction (RT- PCR) is the main pillar in infection control, management, and response to treatment due to... The content of this RSS Feed (c) The Royal Society of Chemistry
Publication date: Available online 30 May 2020Source: American Journal of Kidney DiseasesAuthor(s): Kristen L. King, S. Ali Husain, Sumit Mohan
We thank Nabatchikova et al.1 and Shiba et al.2 for their interest and comments on our work.3 First, we would like to explain that the main reason for predicting an event (hepatocellular carcinoma [HCC] in this case) is to guide future action (for example HCC screening). In our study, our initial aim was to identify a su bpopulation of patients with compensated advanced chronic liver disease (cACLD), in whom HCV had been cured, who could avoid HCC surveillance; unfortunately, we failed. All HCV-cured patients with cACLD need continued HCC screening.
We read with great interest the article by M. Pons and colleagues in which they estimated the incidence of liver-related events and predictive ability of non-invasive markers of liver fibrosis after successful antiviral therapy for HCV infection.1 In this prospective 2 center study from Spain, including patients with HCV-related compensated advanced chronic liver disease (liver stiffness (LS) ≥10 kPa), hepatocellular carcinoma (HCC) developed in 4.4% (25/572) of cases within 2.8 years of the end of treatment (EOT).
Hepatitis B virus (HBV) is a virus species belonging to Hepadnaviridae family which is partial double-stranded DNA viruses (Pourkarim et al., 2014). This virus affects nearly 2 billion people around the world (Wang et al., 2019) and it has been reported as one of the two major causing and risk factors (the second is Hepatitis C Virus) for hepatocellular carcinoma (HCC) in the Sudan (Abou et al., 2009). Several studies have characterized HBV as extremely endemic in Sudan as the hepatitis B surface antigen HBsAg was reported to have a prevalence of approximately 16%-20% in the Sudanese population rate (Elduma and Saeed, 2011).